by Madaline Spencer | Jun 18, 2025
Leticia Orsatti, MD, Vice President of Clinical Development and Medical Affairs at Boehringer Ingelheim, discusses results from clinical trials examining the safety and efficacy of nerandomilast to treat patients with idiopathic pulmonary fibrosis (IPF) or progressive...
by Madaline Spencer | Jun 17, 2025
Deb Jennings, Head of North America Patient Services Operations at Kyowa Kirin, discusses evolving policy landscapes for rare disease access. In a panel discussion at the 2025 World Orphan Drug Congress, Ms. Jennings explained the volatility of the...
by Madaline Spencer | Jun 16, 2025
Katie Niemeyer, patient advocate, discusses her experience with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). SJS/TEN is a very severe reaction that causes skin tissue to die and detach. SJS and TEN previously were thought to be separate...
by Madaline Spencer | Jun 13, 2025
The U.S. Food and Drug Administration (FDA) has approved taletrectinib for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). ROS1-positive NSCLC is a rare and aggressive lung cancer that typically occurs in...
by Madaline Spencer | Jun 13, 2025
Robert Mitchell-Thain, chair of the PBC Foundation, discusses how linerixibat reduces itching in patients with primary biliary cholangitis (PBC). PBC is a chronic, progressive autoimmune liver disease in which the bile ducts become inflamed and damaged....
